The present invention provides an immunoassay method for the highly Sensitive detection of amphetamines, methamphetamines, and methylenedioxy designer amphet amines in urine Samples. Commercially available reagents for the determination of amphetamines and methamphet amines are used with a calibrator comprising a known amount of a Substance Selected from the group consisting of methylenedioxy designer amphetamines. This invention relates generally to the field of measuring an analyte in a liquid medium. More Specifically, it relates to an assay for the measurement of a drug of abuse in a biological Sample. In particular, the invention relates to a highly Sensitive immunoassay method for the detection of amphetamines, methamphetamines, Structurally related drugs. Such as 3,4-methylenedioxymethamphetamine (MDMA) and metabolites of these drugs in biological The abuse of these designer amphetamines is increasing throughout the World, and their detection by Screening methods is becoming a more important issue. Zhao, H. et al., JAnal. Toxicology Vol. 25, PD 258-269(2001) found 71% of urine samples from rave party attendees contained MDMA or MDA alone or in combination with amphetamine or other designer amphetamines such as MDEA. Presently there are no commercial immunoassays designed Specifically for the detection of these Substances, and their detection therefore depends on the relative croSS-reactivities they exhibit in the amphetamine or methamphetamine Screening method used. In general, the croSS-reactivity of the commercially available amphetamine and methamphetamine assays toward many of these compounds is low which Suggests the possibility that Some positive Samples may go undetected.
In testing for drugs of abuse, immunoassays, particularly competitive binding immunoassays, have proven to be espe cially advantageous. In competitive binding immunoassays, an analyte in a biological Sample competes with a labeled reagent, or analyte analog, or tracer, for a limited number of receptor binding sites on antibodies Specific for the analyte and analyte analog. Enzymes Such a 3-galactosidase and The concentration of analyte in the Sample determines the amount of analyte analog which will bind to the antibody. The amount of analyte analog that will bind is inversely proportional to the concentration of analyte in the Sample, because the analyte and the analyte analog each bind to the antibody in proportion to their respective concentrations. The amount of free or bound analyte analog can then be determined by methods appropriate to the particular label being used.
Gas chromatography/mass spectrometry (GC/MS) is highly specific and has been described for the 
SUMMARY OF THE INVENTION
Quite Surprisingly, it has been discovered that a highly Specific immunoassay method for the detection of amphetamines, methamphetamines, Structurally related drugs. Such as 3,4-methylenedioxymethamphetamine (MDMA) and their metabolites in urine samples can be achieved by the use of a calibrator comprising a Substance Selected from the group consisting of methylenedioxy designer amphetamines in drug free, normal human urine and an antibody having Specificity for amphetamine or methamphetamine and croSS-reactivity with amphetamine analogues of methylenedioxyphenylalkylamines.
In the method of the invention, a Sample Suspected of containing amphetamine, methamphetamine or a structur ally related drug is combined with an antibody having Specificity for amphetamine or methamphetamine and a labeled binding partner which can interact with the combi nation of antibody and its corresponding analyte So as to detect the presence of the analytes at Selected cutoff levels either alone or in combination. The particular antibody or antibodies used must have cross-reactivity with amphet amine analogues of methylenedioxyphenylalkylamines. This invention can be used with any type of immunoassay format, e.g., turbidiometric agglutination assay, radioimmunoassay, enzyme immunoassay, or fluorescent polarization immunoassay. Especially preferred is the use of the present invention with agglutinometric formats Suscep tible to an instrumental method for the measurement of the changes brought about by the agglutination reaction. Both manual as well as automated apparatus testing may be Suitably employed for Such agglutinometric analysis. Typically, automated instrumentation will operate utilizing a multiplicity of reagent containers or reservoirs from which will be pipetted the appropriate amount of each reagent for addition to the Sample. For immunoassayS. Such as the Subject agglutination assay, this will usually involve at least US 6,534.325 B1 3 two Such containers, typically, one for an antibody reagent and the other for the microparticles bound with the corre sponding ligand. Additional containers or reservoirs may be present in Some instruments containing diluent, buffers or other additives for appropriate treatment of the Sample.
The clinical analyzer pipettes the onboard reagents and Samples into one cuvette where the competitive agglomera tion reaction occurs and measurement of the turbidity is made. For example, using the HITACHI 917 analyzer (Roche Diagnostics) and the ABUSCREENCE OnLine Amphetamines reagent kit (Roche Diagnostics, Cat. No. 1985965) , urine sample is pipetted with sample diluent into the cuvette, followed immediately by the appropriate amount of antibody reagent and mixing. An initial Spectro photometer reading is taken. Then the appropriate quantity of microparticle reagent is transferred to the cuvette and the reaction mixed. After a brief incubation, a final turbidity measurement is made. The overall change in turbidity (absorbance) in the reaction is compared to a calibration curve and results reported in ng/ml.
The present invention also encompasses a reagent test kit which comprises, in packaged combination, an antibody Specific for amphetamine, an antibody Specific for methamphetamine, a complex comprising a ligand of amphetamine or an amphetamine derivative coupled to a labeling moiety, and a calibrator comprising a known amount of a Substance Selected from the group consisting of methylenedioxy designer amphetamines. Such a test kit provides reagents for an assay with enhanced clinical Sen sitivity for MDMA and structurally-related compounds. FIG. 2 is a dose response curve generated using the assay of the present invention comprising an antibody Specific for amphetamine, an antibody Specific for methamphetamine and calibrators comprising known amounts of MDMA.
FIG. 3 is a dose response curve generated using the assay of the present invention comprising an antibody Specific for amphetamine, an antibody Specific for methamphetamine and calibrators comprising known amounts of MDA. Commercial immunoassay kits for determination of MDMA are currently not available. The only way to deter mine MDMA via immunoassay is to use reagents or a reagent kit for determining amphetamine or methamphet amine comprising an amphetamine antibody and metham phetamine antibody having high croSS-reactivity with MDMA and using amphetamine or methamphetamine as a calibrator. In the present invention, a Substance Selected from the group consisting of methylenedioxy designer amphetamines is used to calibrate a commercially available assay using antibodies for amphetamine and methamphet amine. The use of a methylenedioxy designer amphetamine calibrator Significantly increased the clinical Sensitivity for MDMA, MBDB.MDA, MDE, and BDB without significant increase for medications Such as B-hydroxyphenylamines, e.g., ephedrine, pseudoephedrine, phentamine, tyramine and phenylpropanolamine (PPA). Cross-reactivities of currently marketed assays for MDMA and MDA, according to published literature, as well as croSS-reactivities using the method of the present inven tion are listed in the table below.
By "methylenedioxy designer amphetamines' is meant the group of amphetamine analogues of methylenediox yphenylalkylamines including methylenedioxyamphet amine (MDA), methylenedioxymethamphetamine (MDMA, Ecstasy), methylenedioxyethylamphetamine (MDEA), N-methylbenzodioxazolylbutanamine (MBDB) and benzodioxazol-5-yl-2-butanamine (BDB). 9. A kit for conducting an assay for the determination of an analyte Selected from the group consisting of amphetamine, methamphetamine, and methylenedioxy designer amphetamines in a biological Sample comprising in packaged combination:
a. an antibody Selected from the group consisting of antibodies Specific for amphetamine and having croSS reactivity with amphetamine analogues of methylene dioxyphenylalkylamine and antibodies Specific for methamphetamine and having croSS-reactivity with amphetamine analogue S of methylenedioxyphenylalkylamine, b. a complex comprising a ligand of amphetamine or an amphetamine derivative coupled to a labeling moiety, and c. a calibrator comprising a known amount of a Substance Selected from the group consisting of methylenedioxy designer amphetamines.
10. The method of claim 9, wherein said Substance is MDMA. 11. The method of claim 1, wherein the methylenedioxy de Signer amphetamine analyte is 3,4-methylenedioxymethamphetamine (MDMA).
